New hope for tough lymphoma: phase 3 trial pits duvelisib against standard chemo
Disease control
Recruiting now
This study tests a new drug, duvelisib, against two standard chemotherapy drugs (gemcitabine or bendamustine) in people with a rare type of T-cell lymphoma that has returned or not responded to prior treatment. The main goal is to see if duvelisib can delay cancer growth longer t…
Phase: PHASE3 • Sponsor: SecuraBio • Aim: Disease control
Last updated May 17, 2026 05:35 UTC